CAMBRIDGE, Mass.--(BUSINESS WIRE)--AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO) today announced that previously reported clinical data evaluating its lead product candidate tivozanib will be featured at the 3rd European Multidisciplinary Meeting on Urological Cancers (EMUC 2011) in Barcelona, Spain, November 4-6, 2011. In addition, new data evaluating tivozanib will be presented at the 2011 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in San Francisco, November 12-16, 2011.
